$34.29-4.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 9, 2026
Maze is developing oral medicines for people with genetically defined kidney diseases and inherited metabolic disorders.
Just reported
From Maze Therapeutics, Inc.'s results release of November 9, 2026; its quarterly report has since been filed.
Actual
$0.00
Guided
—
No guide given
Actual
-$0.79
Guided
—
No guide given
Actual
-$51.5M
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$48M | -$30.1M | -59.43% |
| Profit per share | -$0.79 | -$0.66 | -19.70% |
| Free Cash Flow | -$33.1M | -$24.7M | -34.08% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Maze Therapeutics, Inc. reported on November 9, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Completing enrollment in HORIZON with more than 50 patients across three cohorts marks an important milestone for MZE829 and exceeded our target enrollment of 10-15 patients per cohort,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Maze Therapeutics, Inc.’s Item 2.02 8-K filed November 9, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.